BTG Acquires Rights to Infusion Fluids Technology

Exclusive rights to new technology covering the next generation of infusion fluids for dialysis, stroke, and head trauma have been obtained by BTG Plc (London, UK) from Shimizu Pharmaceutical Co., Ltd. (Tokyo, Japan). BTG acquires, develops, and licenses intellectual property rights covering innovative products and processes. Shimizu has developed many kinds of dialysis solutions for artificial kidneys and is now developing a new anticoagulant drug and a drug for the treatment of diseases of the fibrinogenolytic system.

The combined portfolio of patents from Shimizu and BTG creates a strong platform for the development of new parenteral solutions containing ketone bodies. In the longer term, the technology platform may also have applications in the development of new oral therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, epilepsy, and diabetes.

BTG plans to first focus on the perenteral fluids markets. The new products developed could provide a more effective alternative to Lactated Ringer's solution and the dialysis fluid now used by peritoneal dialysis patients and for treating trauma and surgical patients. Ketone body fluids offer increased efficiency of the heart following low perfusion, a physiologic means of overcoming insulin resistance, and an alternative energy source to glucose in the brain during ischemia/hypoxia, preventing brain dysfunction and swelling after brain injury.



Related Links:
BTG